Article

A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients.

Department of Psychiatry, Indiana University School of Medicine, IN 46202, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 03/2005; 66(2):195-8. DOI: 10.4088/JCP.v66n0206
Source: PubMed

ABSTRACT The purpose of this study was to investigate the effectiveness of zonisamide in the treatment of bipolar depression.
Ten patients with DSM-IV bipolar disorder, depressed phase, who had either not tolerated or not responded to previous treatments were given zonisamide in this add-on open-label study. Zonisamide treatment was started at 100 mg/day and increased by 100 mg every 2 weeks to a maximum of 300 mg/day in divided doses (b.i.d. or t.i.d.). Subjects underwent weekly visits at which they were administered the 17-item Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), and Clinical Global Impressions scale (CGI). Every 2 weeks, subjects also underwent laboratory tests, a urine examination, and a verbal memory test. Outcome measures were analyzed with repeated-measures analysis of variance.
Eight subjects completed all 8 weeks of the study. Two subjects completed more than 4 weeks of the study, and their data were analyzed using the last observation carried forward. Bipolar depression subjects had a significant reduction in HAM-D scores (p < .001) and in CGI-Improvement (CGI-I) scores (p < .001). Five of 8 subjects who completed all 8 weeks of the study had more than a 50% decrease in HAM-D scores and were rated much improved on the CGI-I at the end of 8 weeks of treatment. There was no significant drug effect on YMRS scores, weight, or verbal memory.
Zonisamide may be a useful drug in the treatment of bipolar depression. Further controlled clinical trials are needed.

0 Followers
 · 
201 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent research suggests a potential role for a new generation of anticonvulsant drugs, including zonisamide, in the treatment of alcohol dependence. Some elements of the central mechanism of action that zonisamide has in common with ethanol, give rise to the question of whether there is an interaction between these two agents and whether there is any risk associated with the enhanced depressive effect of these agents on the central nervous system.
    Alcohol and alcoholism (Oxford, Oxfordshire). Supplement 06/2014; DOI:10.1093/alcalc/agu024
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective Antiepileptic drugs (AE) such as valpro- ate and carbamazepine are today widely used in psychiatry. Recently, lamotrigine has been approved for the prevention of depressive recurrences in bipolar disor- der. Some of the new AEs such as oxcar- bazepine, gabapentin, topiramate, leve- tiracetam, pregabalin and zonisamide have been reported to be effective in the treatment of several resistant mood, anxiety, impulse control, substance use, eating and personality disorders. In the present article we systematically review the available literature on the use of zonisamide in psychiatry. Method Medline, Embase, PsychInfo databases were searched for existing studies of zonisamide in mental, mood, anxiety, and eating disorders. Inquiry to Eisai pharmaceuticals and manual search on significant book chapters and reviews on the same topic were also performed. Results Zonisamide shows an anticonvulsant action in patients with partial, gen- Introduzione eralized and combined seizures. The mechanism of action is not complete- ly known, but zonisamide stabilizes neuronal cell activity and suppresses neuronal hypersynchronization. This mechanism could also be responsible for the antianxiety, antimanic, anti- depressant and anti-impulsive action of the drug. Most clinical studies on zonisamide are open, non-random- ized, and involve small samples; therefore the results should still be considered preliminary (Tab. I). With these limitations, the data reported seem to indicate efficacy of the drug as adjunctive treatment of various treatment-resistant patients with bipo- lar and eating disorders, and obesity. Zonisamide is well tolerated; howev- er drop-out rates are high; most fre- quently reported side effects include somnolence, depression, and cogni- tive disturbances. Conclusion The available information on zonisamide in different mental disorders should be considered preliminary. Although re- ported results are encouraging, further controlled research in larger samples is necessary.
    Giornale Italiano di Psicopatologia 01/2008; 18:316-323.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess preliminarily the effectiveness of zonisamide in bulimia nervosa. This was an open-label, prospective, 12-week, flexible dose study of zonisamide in bulimia nervosa. The primary outcome was binge-purge episode frequency. Twelve individuals received zonisamide, 10 completed at least one post-baseline evaluation, and six completed the study. Mean dose at endpoint was 420 (SD = 215) mg/day. Zonisamide was associated with significant reductions in frequency of binge-purge episodes and binge-purge days as well as measures of binge eating behavior, purging behavior, clinical severity, obsessive-compulsive features, and depressive symptoms. Weight was unchanged. In this open-label trial, zonisamide was effective in bulimia nervosa, but associated with a high discontinuation rate. © 2013 Wiley Periodicals, Inc.(Int J Eat Disord 2013).
    International Journal of Eating Disorders 11/2013; 46(7). DOI:10.1002/eat.22159 · 3.03 Impact Factor